


Pharmaceuticals & Biotechnology | Mid Cap
Ipca Laboratories demonstrates a mixed financial performance. The company shows strong solvency due to a high equity ratio and minimal debt. Growth prospects appear promising, driven by robust revenue, operating profit, and EPS growth rates. However, certain areas need attention, particularly liquidity, which is currently weak. While profitability metrics such as gross profit margin, ROCE, and ROA are good, some financial metrics like adjusted EPS and net margin need improvement. The company's efficiency in utilizing assets is inconsistent, with a strong capital turnover ratio but weak fixed asset and inventory turnover. Overall, Ipca Laboratories exhibits potential for continued growth and profitability, but must address its liquidity and efficiency challenges to realize its full potential.
Ipca Laboratories demonstrates a mixed financial performance. The company shows strong solvency due to a high equity ratio and minimal debt. Growth prospects appear promising, driven by robust revenue, operating profit, and EPS growth rates. However, certain areas need attention, particularly liquidity, which is currently weak. While profitability metrics such as gross profit margin, ROCE, and ROA are good, some financial metrics like adjusted EPS and net margin need improvement. The company's efficiency in utilizing assets is inconsistent, with a strong capital turnover ratio but weak fixed asset and inventory turnover. Overall, Ipca Laboratories exhibits potential for continued growth and profitability, but must address its liquidity and efficiency challenges to realize its full potential.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
38.85
Industry Median
30.92
Mid Cap Median
41.06
P/E RATIO
38.55
P/B RATIO
5.45
Industry Median
3.39
Mid Cap Median
7.42
P/S RATIO
4.70
Industry Median
3.36
Mid Cap Median
6.69
Others
PEG RATIO
52.10
EV/EBITDA RATIO
21.76
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1734.2 as on Aug 6, 2026.
The company exhibits strong growth prospects. The company benefits from robust revenue growth, operating profit growth, and EPS growth rates. This indicates a healthy expansion in its core business and profitability. The company's growth trajectory positions it favorably for future success and value creation. However, the company should ensure that this growth is sustainable and well-managed to maintain its financial health.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 7.45 | 7.02 | 23.5 | 16.12 | 8.42 |
| Operating Profit Growth Rate | -14.63 | -29.66 | 42.06 | 30.74 | 14.33 |
| Earnings Per Share (EPS) Growth | -22.45 | -46.69 | 16.09 | 34.82 | 54.68 |
| Asset Growth Rate | 25.65 | 13.13 | 28.69 | 5.83 | 5.33 |
| Net Income Growth Rate | -22 | -46.18 | 9.19 | 50.1 | 50.83 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 42.18 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 2 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 3 | Gland Pharma Ltd | 7.91 | 41.83 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 4 | Neuland Laboratories Ltd | 7.84 | 75.93 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 41.06 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.60 | 24.31 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 39.72 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Syngene International Ltd | 7.16 | 50.86 | Overvalued | 918.00 | 7.55 | 317.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 30.92 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Laurus Labs Ltd | 7.10 | 111.18 | Neutral | 1778.00 | 13.71 | 890.00 |
| 11 | Glenmark Pharmaceuticals Ltd | 6.36 | 47.04 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 12 | Ipca Laboratories Ltd | 6.33 | 38.55 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 13 | Piramal Pharma Ltd | 5.83 | -85.00 | Neutral | 922.00 | 5.26 | -326.00 |
| 14 | Jubilant Pharmova Ltd | 5.71 | 37.02 | Neutral | 1260.00 | 1.25 | 398.00 |
| 15 | Natco Pharma Ltd | 5.69 | 11.52 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 16 | Wockhardt Ltd | 5.07 | 150.65 | Neutral | 652.00 | 19.51 | 199.00 |
| 17 | Pfizer Ltd | 3.45 | 48.81 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral